Claims for Patent: 8,497,393

Summary for Patent: 8,497,393

Title:	Process to prepare treprostinil, the active ingredient in Remodulin®
Abstract:	This present invention relates to an improved process to prepare prostacyclin derivatives. One embodiment provides for an improved process to convert benzindene triol to treprostinil via salts of treprostinil and to purify treprostinil.
Inventor(s):	Hitesh Batra, Sudersan M. TULADHAR, Raju Penmasta, David A. Walsh
Assignee:	United Therapeutics Corp
Application Number:	US13/548,446
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,497,393
Patent Claims:	1. A product comprising a compound of formula I or a pharmaceutically acceptable salt thereof, wherein said product is prepared by a process comprising (a) alkylating a compound of structure II with an alkylating agent to produce a compound of formula III, wherein w=1, 2, or 3; Y1 is trans-CH═CH—, cis-CH═CH—, —CH2(CH2)m—, or —C≡C—; m is 1, 2, or 3; R7 is (1) —CpH2p—CH3, wherein p is an integer from 1 to 5, inclusive, (2) phenoxy optionally substituted by one, two or three chloro, fluoro, trifluoromethyl, (C1-C3) alkyl, or (C1-C3)alkoxy, with the proviso that not more than two substituents are other than alkyl, with the proviso that R7 is phenoxy or substituted phenoxy, only when R3 and R4 are hydrogen or methyl, being the same or different, (3) phenyl, benzyl, phenylethyl, or phenylpropyl optionally substituted on the aromatic ring by one, two or three chloro, fluoro, trifluoromethyl, (C1-C3)alkyl, or (C1-C3)alkoxy, with the proviso that not more than two substituents are other than alkyl, (4) cis-CH═CH—CH2—CH3, (5) —(CH2)2—CH(OH)—CH3, or (6) —(CH2)3—CH═C(CH3)2; —C(L1)—R7 taken together is (1) (C4-C7)cycloalkyl optionally substituted by 1 to 3 (C1-C5)alkyl; (2) 2-(2-furyl)ethyl, (3) 2-(3-thienyl)ethoxy, or (4) 3-thienyloxymethyl; M1 is α-OH:β-R5 or α-R5β-OH or α-OR1:β-R5 or α-R5:β-OR2, wherein R5 is hydrogen or methyl, R2 is an alcohol protecting group, and L1 is α-R3:β-R4, α-R4:β-R3, or a mixture of α-R3:β-R4 and α-R4:β-R3, wherein R3 and R4 are hydrogen, methyl, or fluoro, being the same or different, with the proviso that one of R3 and R4 is fluoro only when the other is hydrogen or fluoro, (b) hydrolyzing the product of formula III of step (a) with a base, (c) contacting the product of step (h) with a base B to form a salt of formula Is. (d) optionally reacting the salt formed in step (c) with an acid to form the compound of formula I. 2. The product of claim 1, wherein the purity of compound of formula I in said product is at least 99.5%. 3. The product of claim 1, wherein the alkylating agent is Cl(CH2)wCN, Br(CH2)wCN, or I(CH2)wCN. 4. The product of claim 1, wherein the base in step (b) is KOH or NaOH. 5. The product of claim 1, wherein the base B in step (c) is selected from the group consisting of ammonia, N-methylglucamine, procaine, tromethanine, magnesium, L-lysine, L-arginine, triethanolamine, and diethanolamine. 6. The product of claim 1, wherein the acid in step (d) is HCl or H2SO4. 7. The product of claim 1, wherein Y1 is —CH2CH2—; M1 is α-OH:β-H or α-H:β-OH; —C(L1)-R7 taken together is —(CH2)4CH3; and w is 1. 8. The product of claim 1, wherein the process does not include purifying the compound of formula (III) produced in step (a). 9. A product comprising a compound having formula IV or a pharmaceutically acceptable salt thereof, wherein the product is prepared by the process comprising (a) alkylating a compound of formula V with an alkylating agent to produce a compound of formula VI, (b) hydrolyzing the product of formula VI of step (a) with a base, (c) contacting the product of step (h) with a base B to form a salt of formula IVs, and (d) optionally reacting the salt formed in step (c) with an acid to form the compound of formula IV. 10. The product of claim 9, wherein the purity of product of step (d) is at least 99.5%. 11. The product of claim 9, wherein the alkylating agent is ClCH2CN. 12. The product of claim 9, wherein the base in step (b) is KOH. 13. The product of claim 9, wherein the base B in step (c) is selected from a group consisting of ammonia, N-methylglucamine, procaine, tromethanine, magnesium, L-lysine, L-arginine, triethanolamine, and diethanolamine. 14. The product of claim 9, wherein the base B is diethanolamine. 15. The product of claim 9, wherein the acid in step (d) is HCl. 16. The product of claim 9, wherein the process does not include purifying the compound of formula (VI) produced in step (a). 17. The product of claim 16, wherein the base B in step (c) is selected from a group consisting of ammonia, N-methylglucamine, procaine, tromethanine, magnesium, L-lysinc, L-arginine, tricthanolamine, and diethanolamine. 18. The product of claim 17, wherein the base B is diethanolamine. 19. The product of claim 1, wherein the base in step (b) is KOH or NaOH and wherein the base 13 in step (c) is selected from the group consisting of ammonia. N-methyl glucamine, procaine, tromethanine, magnesium, L-lysine, L-arginine, triethanolamine, and diethanolamine. 20. The product of claim 9, wherein the base in step (b) is KOH or NaOH and wherein the base B in step (c) is selected from the group consisting of ammonia, N-methylglucamine, procaine, tromethanine, magnesium, L-lysine, L-arginine, triethanolamine, and diethanolamine. 21. The product of claim 1, wherein step (d) is performed. 22. The product of claim 21, wherein the product comprises a pharmaceutically acceptable salt formed from the product of step (d).